Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice

Infliximab tolerance in patients with rheumatoid arthritis in real clinical practice

A wide range of biological agents recently introduced into clinical rheumatology determines a special interest in their tolerance. The paper presents the authors’ own data, as well as a review of foreign literature on this issue.Objective: to analyze the tolerability of infliximab (INF) in patients...

Full description

Bibliographic Details
Main Authors:	E. S. Aronova, G. V. Lukina, Ya. A. Sigidin
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2020-02-01
Series:	Научно-практическая ревматология
Subjects:	biological therapy biological agents infliximab tumor necrosis factor-а inhibitors adverse reactions rheumatoid arthritis
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2840

Similar Items

EFFICACY OF INFLIXIMAB IN RHEUMATOID ARTHRITIS: A RELATIONSHIP TO THE TOTAL DOSE OF THE DRUG
by: E. S. Aronova, et al.
Published: (2015-10-01)

Clinical experience with infliximab administration in patients with rheumatoid arthritis by Russian register data
by: Galina Viktorovna Lukina, et al.
Published: (2009-08-01)

Infliximab in the therapy of rheumatoid arthritis
by: G. V. Lukina, et al.
Published: (2016-05-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-01-01)

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting
by: Mayara Costa de Camargo, et al.
Published: (2019-09-01)

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.
by: Mohammed A. Al-Karkhi, et al.
Published: (2015-10-01)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
by: Iannone F, et al.
Published: (2022-06-01)

COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
by: M. A. Borisova, et al.
Published: (2017-01-01)

Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up
by: E. S. Aronova, et al.
Published: (2020-06-01)

Cost-effectiveness Analysis of Reference Infliximab (Remicade) Compared to its Biosimilar (Remsima) in Iraqi Patients with Rheumatoid Arthritis (Conference Paper )#
by: Hasan Raid Fadhil, et al.
Published: (2023-02-01)

Drug-induced pityriasis lichenoides from infliximab in a patient with juvenile idiopathic arthritis
by: Nicole Boswell, BS, et al.
Published: (2022-05-01)

Evaluation of myocardial damage in different types of rheumatoid arthritisduring disease-modifying antirheumatic drug or biological therapy (with infliximab)
by: V I Mazurov, et al.
Published: (2010-12-01)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
by: Laetitia Diep, et al.
Published: (2022-10-01)

INFLIXIMAB-INDUCED LUPUS-LIKE SYNDROME IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS (A CASE REPORT): AN ACCIDENT OR REGULARITY?
by: Yu. V. Muravyev, et al.
Published: (2017-09-01)

Russian registry of Infliximab.Impact of therapy on the functional status of patients with rheumatoid arthritis
by: V N Amirdzhanova, et al.
Published: (2010-12-01)

GOUT – induced by Infliximab?- case report
by: Anca Chiriac, et al.
Published: (2012-10-01)

Effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions
by: Chamaida ePlasencia, et al.
Published: (2015-10-01)

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab
by: Ellis LA, et al.
Published: (2019-01-01)

EFFECT OF INFLIXIMAB ON PARAMETERS OF REMODELING OF ARTERIAL BLOODSTREAM, RANKL AND OSTEOPROTEGERIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Larisa Aleksandrovna Knyazeva, et al.
Published: (2014-02-01)

Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel Alleviates Pain and Protects Cartilage in Rheumatoid Arthritis
by: Chen W, et al.
Published: (2020-12-01)

The Impact of Early Optimization of Infliximab Blood Concentrations >1 μg/mL on Therapeutic Effectiveness in Rheumatoid Arthritis
by: Yuji Nozaki, et al.
Published: (2023-04-01)

Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication
by: Bonafede MMK, et al.
Published: (2016-12-01)

PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
by: E. L. Nasonov
Published: (2017-09-01)

METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
by: E. L. Nasonov
Published: (2016-12-01)

METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
by: E. L. Nasonov
Published: (2015-09-01)

METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
by: E. L. Nasonov
Published: (2015-10-01)

Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry
by: Nancy Shadick, et al.
Published: (2023-05-01)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
by: Proton Rahman, et al.
Published: (2020-09-01)

Derlin-1, as a Potential Early Predictive Biomarker for Nonresponse to Infliximab Treatment in Rheumatoid Arthritis, Is Related to Autophagy
by: Yongsong Cai, et al.
Published: (2022-01-01)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
by: van der Maas Aatke, et al.
Published: (2012-09-01)

Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
by: E. A. Strel’tsov
Published: (2018-10-01)

Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy
by: Hironori Kawamoto, M.D., et al.
Published: (2017-01-01)

The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study
by: Boyoon Choi, et al.
Published: (2022-08-01)

Portal Venous ThrombosisDisseminated Tuberculosis in Rheumatoid Arthritis
by: Vasanthi Natarajan, et al.
Published: (2017-06-01)

THE EUROPEAN CONGRESS OF RHEUMATOLOGY (PARIS, 11–14 JUNE 2014): PROBLEMS OF RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2014-12-01)

THE EFFECT OF ABATACEPT ON BLOOD BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: M. A. Borisova, et al.
Published: (2017-09-01)

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
by: Clifton O. Bingham, et al.
Published: (2023-02-01)

BIOLOGICAL THERAPY AND INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RELEVANCE AND PROSPECTS
by: B. S. Belov
Published: (2014-06-01)

Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study
by: Haya M. Almalag, et al.
Published: (2022-07-01)